Impact of Diabetes in Patients Diagnosed With COVID-19
Tóm tắt
Từ khóa
Tài liệu tham khảo
Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058
Zhou, 2015, Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis, Virol J, 12, 218, 10.1186/s12985-015-0446-6
Chan, 2015, Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease, Clin Microbiol Rev, 28, 465, 10.1128/CMR.00102-14
Muniyappa, 2020, COVID-19 pandemic, coronaviruses, and diabetes mellitus, Am J Physiol Endocrinol Metab, 318, E736, 10.1152/ajpendo.00124.2020
Li, 2020, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol, 109, 10.1007/s00392-020-01626-9
Maddaloni, 2020, Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I), Diabetes Res Clin Pract, 108454, 10.1016/j.diabres.2020.108454
Onder, 2020, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy, JAMA, 323, 10.1001/jama.2020.4683
Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 10.1016/S0140-6736(20)30566-3
Wu, 2020, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, 180, 10.1001/jamainternmed.2020.0994
Guan, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, 382, 10.1056/NEJMoa2002032
Andersen, 2016, Impact of Obesity and Metabolic Syndrome on Immunity, Adv Nutr, 7, 66, 10.3945/an.115.010207
Francisco, 2019, Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases, Biochem Pharmacol, 165, 196, 10.1016/j.bcp.2019.03.030
Francisco, 2018, Obesity, Fat Mass and Immune System: Role for Leptin, Front Physiol, 9, 10.3389/fphys.2018.00640
Andrade-Oliveira, 2015, Adipokines as drug targets in diabetes and underlying disturbances, J Diabetes Res, 2015, 681612, 10.1155/2015/681612
Bremer, 2013, Adipose tissue dysfunction in nascent metabolic syndrome, J Obes, 2013, 393192, 10.1155/2013/393192
Faber, 2009, Role of adipose tissue in haemostasis, coagulation and fibrinolysis, Obes Rev, 10, 10.1111/j.1467-789X.2009.00593.x
Ouchi, 2011, Adipokines in inflammation and metabolic disease, Nat Rev Immunol, 11, 85, 10.1038/nri2921
Richard, 2017, Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy, BMJ Open Diabetes Res Care, 5, e000379, 10.1136/bmjdrc-2016-000379
Luzi, 2020, Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic, Acta Diabetol, 57, 10.1007/s00592-020-01522-8
Karlsson, 2016, Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination, mBio, 7, 10.1128/mBio.01144-16
Magdy Beshbishy, 2020, Factors Associated with Increased Morbidity and Mortality of Obese and Overweight COVID-19 Patients, Biol (Basel), 9, 280, 10.3390/biology9090280
Wu, 2020, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, Jama, 323, 10.1001/jama.2020.2648
Kulcsar, 2019, Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight, 4, e131774, 10.1172/jci.insight.131774
Yang, 2006, Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS, Diabetes Med, 23, 10.1111/j.1464-5491.2006.01861.x
Sardu, 2020, Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control, Diabetes Care, 43, 10.2337/dc20-0723
Sardu, 2020, Hyperglycaemia on admission to hospital and COVID-19, Diabetologia, 63, 10.1007/s00125-020-05216-2
Schuetz, 2011, Diabetes and sepsis: preclinical findings and clinical relevance, Diabetes Care, 34, 10.2337/dc10-1185
Drucker, 2020, Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications, Endocr Rev, 41, 10.1210/endrev/bnaa011
Ryan, 2020, COVID 19 and the Patient with Obesity - The Editors Speak Out, Obesity, 28, 847, 10.1002/oby.22808
Imai, 2005, Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature, 436, 10.1038/nature03712
Treml, 2010, Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets, Crit Care Med, 38, 596, 10.1097/CCM.0b013e3181c03009
Bosso, 2020, The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19, Mol Ther Methods Clin Dev, 18, 10.1016/j.omtm.2020.06.017
Vaduganathan, 2020, Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N Engl J Med, 382, 10.1056/NEJMsr2005760
Sardu, 2020, Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy, J Am Heart Assoc, 9, e016948, 10.1161/JAHA.120.016948
Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 10.1161/CIRCULATIONAHA.105.169404
Costa, 2020, Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies, Diabetes Metab Syndr, 14, 10.1016/j.dsx.2020.06.016
Hu, 2020, Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis, J Clin Virol, 127, 104371, 10.1016/j.jcv.2020.104371
Bhatraju, 2020, Covid-19 in Critically Ill Patients in the Seattle Region - Case Series, N Engl J Med, 382, 10.1056/NEJMoa2004500
2020, . Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020, MMWR Morb Mortal Wkly Rep, 69, 10.15585/mmwr.mm6913e2
Zhang, 2020, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, 75, 10.1111/all.14238
Liu, 2020, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin Med J (Engl), 133, 10.1097/CM9.0000000000000744
Guo, 2020, Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, 5, 10.1001/jamacardio.2020.1017
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 10.1016/S0140-6736(20)30211-7
Wang, 2020, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, Jama, 323, 10.1001/jama.2020.1585
Yang, 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis, 94, 10.1016/j.ijid.2020.03.017
Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 8, 10.1016/S2213-2600(20)30079-5
Chen, 2020, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, 368, m1091, 10.1136/bmj.m1091
2020, . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China, Zhonghua Liu Xing Bing Xue Za Zhi, 41, 10.3760/cma.j.issn.0254-6450.2020.02.003
Singh, 2020, Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Syndr, 14, 10.1016/j.dsx.2020.04.004
Ali, 2020, Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait, medRxiv, 2020.08.20.20178525
Wang, 2020, Comorbidities and multi-organ injuries in the treatment of COVID-19, Lancet, 395, e52, 10.1016/S0140-6736(20)30558-4
Carsana, 2020, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study, Lancet Infect Dis, 20, 10.1016/S1473-3099(20)30434-5
Sardu, 2020, Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19, Cardiovasc Diabetol, 19, 76, 10.1186/s12933-020-01047-y
Marfella, 2020, Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients, Diabetes Metab, 46, 403, 10.1016/j.diabet.2020.05.005
Feng, 2006, Cloning, chromosome mapping and expression characteristics of porcine ANGPTL3 and -4, Cytogenet Genome Res, 114, 10.1159/000091927
Gupta, 2019, The stimulation of thrombosis by hypoxia, Thromb Res, 181, 77, 10.1016/j.thromres.2019.07.013
Sardu, 2020, Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence, J Clin Med, 9, 10.3390/jcm9051417
Alshukry, 2020, Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait, medRxiv, 2020.06.14.20131045, 10.1101/2020.10.11.20210740
Maddaloni, 2020, Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II), Cardiovasc Diabetol, 19, 164, 10.1186/s12933-020-01140-2
Alahmad, 2020, Fasting Blood Glucose and COVID-19 Severity: Nonlinearity Matters, Diabetes Care, dc201941, 10.2337/dc20-1941
Hamming, 2004, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J Pathol, 203, 10.1002/path.1570
Verdecchia, 2020, The pivotal link between ACE2 deficiency and SARS-CoV-2 infection, Eur J Intern Med, 76, 14, 10.1016/j.ejim.2020.04.037
Lukassen, 2020, SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells, EMBO J, 39, e105114, 10.15252/embj.20105114
Zou, 2020, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front Med, 14, 10.1007/s11684-020-0754-0
Roca-Ho, 2017, Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse, Int J Mol Sci, 18, 563, 10.3390/ijms18030563
Romaní-Pérez, 2015, Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats, Endocrinology, 156, 10.1210/en.2014-1685
Tikoo, 2015, Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications, Biochem Pharmacol, 93, 10.1016/j.bcp.2014.11.013
Zhang, 2014, Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis, ScientificWorldJournal, 2014, 603409, 10.1155/2014/603409
Wösten-van Asperen, 2011, Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist, J Pathol, 225, 10.1002/path.2987
Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 10.1161/CIRCULATIONAHA.104.510461
Rao, 2020, Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits, Diabetes Care, 43, 10.2337/dc20-0643
Fernandez, 2018, Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality, J Intern Med, 284, 10.1111/joim.12783
Chen, 2020, Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients, medRxiv, 2020.03.22.20040774, 10.1101/2020.03.22.20040774
Yang, 2010, Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes, Acta Diabetol, 47, 10.1007/s00592-009-0109-4
Liu, 2020, Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 Infection, medRxiv, 2020.02.28.20029181, 10.1101/2020.02.28.20029181
Wan, 2020, Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus, J Virol, 94, 10.1128/JVI.00127-20
Li, 2017, The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases, Pharmacol Res, 125, 21, 10.1016/j.phrs.2017.06.005
Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection, Lancet Respir Med, 8, e21, 10.1016/S2213-2600(20)30116-8
Braun, 2019, Furin-mediated protein processing in infectious diseases and cancer, Clin Transl Immunol, 8, e1073, 10.1002/cti2.1073
Harlid, 2017, The Metabolic Syndrome, Inflammation, and Colorectal Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples, Mediators Inflammation, 2017, 4803156, 10.1155/2017/4803156
Bravo, 1994, Accurate and efficient cleavage of the human insulin proreceptor by the human proprotein-processing protease furin. Characterization and kinetic parameters using the purified, secreted soluble protease expressed by a recombinant baculovirus, J Biol Chem, 269, 10.1016/S0021-9258(18)47322-X
Ueyama, 2015, Association of FURIN and ZPR1 polymorphisms with metabolic syndrome, BioMed Rep, 3, 10.3892/br.2015.484
Kayo, 1997, Proprotein-processing endoprotease furin controls growth of pancreatic beta-cells, Diabetes, 46, 10.2337/diabetes.46.8.1296
Louagie, 2008, Role of furin in granular acidification in the endocrine pancreas: identification of the V-ATPase subunit Ac45 as a candidate substrate, Proc Natl Acad Sci U S A, 105, 10.1073/pnas.0800340105
Al-Mulla, 2020, A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine, bioRxiv, 2020.05.16.099176, 10.1101/2020.05.16.099176
Flint, 2020, COVID-19 and obesity-lack of clarity, guidance, and implications for care, Lancet Diabetes Endocrinol, 8, 10.1016/S2213-8587(20)30156-X
Zick, 2003, Role of Ser/Thr kinases in the uncoupling of insulin signaling, Int J Obes Relat Metab Disord, 10.1038/sj.ijo.0802503
El Mesallamy, 2014, The serine protease granzyme B as an inflammatory marker, in relation to the insulin receptor cleavage in human obesity and type 2 diabetes mellitus, J Interferon Cytokine Res, 34, 10.1089/jir.2013.0059
Spence, 2019, IFITM3 directly engages and shuttles incoming virus particles to lysosomes, Nat Chem Biol, 15, 10.1038/s41589-018-0213-2
Wrensch, 2014, IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms, Viruses, 6, 10.3390/v6093683
Thevarajan, 2020, Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19, Nat Med, 26, 10.1038/s41591-020-0819-2
Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052
Shi, 2018, mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3, Proc Natl Acad Sci U S A, 115, E10069, 10.1073/pnas.1811892115
Haga, 2010, TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds, Antiviral Res, 85, 10.1016/j.antiviral.2009.12.001
Haga, 2008, Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry, Proc Natl Acad Sci U S A, 105, 10.1073/pnas.0711241105
Palau, 2020, ADAM17 inhibition may exert a protective effect on COVID-19, Nephrol Dial Transplant, 35, 10.1093/ndt/gfaa093
Xu, 2016, A Disintegrin and Metalloprotease 17 in the Cardiovascular and Central Nervous Systems, Front Physiol, 7, 10.3389/fphys.2016.00469
Togashi, 2002, Effect of TNF-alpha–converting enzyme inhibitor on insulin resistance in fructose-fed rats, Hypertension, 39, 10.1161/hy0202.103290
Serino, 2007, Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes, Diabetes, 56, 10.2337/db07-0360
Ibrahim, 2020, COVID-19 spike-host cell receptor GRP78 binding site prediction, J Infect, 80, 10.1016/j.jinf.2020.02.026
Ye, 2010, Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance, Diabetes, 59, 6, 10.2337/db09-0755
Koch, 1999, T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density, Int Immunol, 11, 10.1093/intimm/11.5.777
Ulrich, 2020, CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Rev Rep, 16, 10.1007/s12015-020-09976-7
Xie, 2019, Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target, J Neuroinflammation, 16, 72, 10.1186/s12974-019-1460-1
Drucker, 2018, Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Cell Metab, 27, 10.1016/j.cmet.2018.03.001
Bloodworth, 2018, Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology, J Allergy Clin Immunol, 142, 683, 10.1016/j.jaci.2018.01.053
Jin, 2020, Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment, Acta Pharm Sin B, 10, 10.1016/j.apsb.2020.05.006
Chatterjee, 2020, SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush, Prim Care Diabetes, 14, 10.1016/j.pcd.2020.05.013
Fernandez-Fernandez, 2020, Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19, J Clin Med, 9, 2030, 10.3390/jcm9072030
2020, 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020, Diabetes Care, 43, S193, 10.2337/dc20-S015
Papadokostaki, 2020, COVID-19 and diabetes: What does the clinician need to know, Prim Care Diabetes, 14, 10.1016/j.pcd.2020.06.010
Bornstein, 2020, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol, 8, 10.1016/S2213-8587(20)30223-0
Chen, 2020, Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication, Diabetes Care, 43, 10.2337/dc20-0660
Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035
Fadini, 2020, Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study, Diabetes Obes Metab, 10.1111/dom.14097
Strollo, 2020, Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths, Diabetes Res Clin Pract, 108444, 10.1016/j.diabres.2020.108444
Cariou, 2020, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia, 63, 10.1007/s00125-020-05180-x
Solerte, 2020, Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study, Diabetes Care, 10.2337/dc20-1521
Monteil, 2020, Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2, Cell, 181, 905, 10.1016/j.cell.2020.04.004